



Ambu A/S - Capital increase in connection with exercise of warrants issued

In December 2013, Ambu A/S issued 400,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 2.50. These warrants were issued to 52 employees with a vesting period of three years and may therefore be exercised in the trading window which was opened 9 November 2017 in connection with Ambu's Annual Report 2016/17.

As a result, one employee has given instruction as to the exercise of 2,000 warrants to the agreed exercise price 66.30 in the current trading window and today, the Board of Directors of Ambu passed a resolution to carry out the capital increase relating to the warrants exercised.

As a result of the capital increase, the share capital of Ambu will be increased by a nominal amount of DKK 5,000 from DKK 124,907,300 to DKK 124,912,300 through the issue of 2,000 Class B shares

Following this exercise of warrants and in consideration of the employees having left the company, 62,000 remaining warrants relating to the 2013 scheme are now being held by 8 individuals.

The new B shares are expected to be admitted to trading and official listing on NASDAQ Copenhagen A/S on 27 November 2017 under the ISIN code of Ambu A/S' existing B shares (DK0060591204).

Under section 10 of the Danish Executive Order on disclosure requirements for issuers, Ambu A/S is to announce the total share capital and the total voting rights by the end of a month in which any change of the share capital was effected. The table below shows the total share capital and the total voting rights of Ambu A/S after the capital increase.

	Number of shares (nominal value DKK 2.5)	Nominal value (DKK)	Voting rights
A shares	6,864,000	17,160,000	68,640,000
B shares	43,100,920	107,752,300	43,100,920
Total	49,964,920	124,912,300	111,740,920

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

About Ambu

Since 1937, breakthrough ideas have driven our work to bring efficient healthcare solutions to life within our fields of excellence: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. Millions of patients and healthcare professionals worldwide depend and rely on the functionality and performance of our products. We are dedicated to improving patient safety and advancing single-use devices. The manifestations of our efforts range from early inventions like the Ambu Bag™ and the legendary Blue Sensor™ electrodes to our latest landmark solutions such as the aScope™ – the world's first flexible single-use videoscope. Our commitment to bringing new ideas and superior service to our customers has made Ambu one of the most recognised medtech companies in the world. Our head office is situated in Ballerup near Copenhagen. Ambu has more than 2,400 employees in Europe, North America, Asia and the Pacific region. You can find more information about Ambu at www.ambu.com.